

Highlights of This Issue 1183

REVIEW

- 1185** **The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?**
Joshua Casaos, Noah L. Gorelick, Sakibul Huq, John Choi, Yuanxuan Xia, Riccardo Serra, Raphael Felder, Tarik Lott, Richard E. Kast, Ian Suk, Henry Brem, Betty Tyler, and Nicolas Skuli

SMALL MOLECULE THERAPEUTICS

- 1195** **Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models**
Mehran Makvandi, Hwan Lee, Laura N. Puentes, Sean W. Reilly, Komal S. Rathi, Chi-Chang Weng, Ho Sze Chan, Catherine Hou, Pichai Raman, Daniel Martinez, Kuiying Xu, Sean D. Carlin, Roger A. Greenberg, Bruce R. Pawel, Robert H. Mach, John M. Maris, and Daniel A. Pryma

- 1205** **TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models**
Chihoko Yoshimura, Hiromi Muraoka, Hiroaki Ochiwa, Shingo Tsuji, Akihiro Hashimoto, Hiromi Kazuno, Fumio Nakagawa, Yu Komiya, Satoshi Suzuki, Toru Takenaka, Masafumi Kumazaki, Naoya Fujita, Takashi Mizutani, and Shuichi Ohkubo

- 1217** **The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β -Catenin**
Samridhhi Shukla, David Milewski, Arun Pradhan, Nihar Rama, Kathryn Rice, Tien Le, Matthew J. Flick, Sara Vaz, Xueheng Zhao, Kenneth D. Setchell, Elsa Logarinho, Vladimir V. Kalinichenko, and Tanya V. Kalin

- 1230** **Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies**
Meghan A. Rice, En-Chi Hsu, Merve Aslan, Ali Ghoochani, Austin Su, and Tanya Stoyanova

- 1243** **The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6**
Jian Cai, Huaiming Wang, Xiaodong Jiao, Rongkang Huang, Qiyuan Qin, Jianwei Zhang, Honglei Chen, Dan Feng, Xin Tian, and Hui Wang

- 1255** **DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas**
Valentina Restelli, Monica Lupi, Rosaria Chilà, Micaela Vagni, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Francesco Bertoni, Giovanna Damia, and Laura Carrassa

- 1265** **17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells**
Sheng Dai, Shu Yang, Xin Hu, Wei Sun, Gregory Tawa, Wenge Zhu, Aaron D. Schimmer, Chao He, Bingliang Fang, Hongbo Zhu, and Wei Zheng

LARGE MOLECULE THERAPEUTICS

- 1278** **IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy**
Nadine Beha, Markus Harder, Sarah Ring, Roland E. Kontermann, and Dafne Müller

- 1289** **A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer**
Jieheng Wu, Donghui Han, Shengjia Shi, Qiang Zhang, Guoxu Zheng, Ming Wei, Yueheng Han, Guodong Li, Fa Yang, Dian Jiao, Pin Xie, Lingling Zhang, An-Gang Yang, Aizhi Zhao, Weijun Qin, and Weihong Wen

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 1302** **Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes**
Lu Zhang, Bridget Riley-Gillis, Priyanka Vijay, and Yu Shen

Table of Contents

1312 TGF β -induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC


Abdul K. Siraj, Poyil Pratheeshkumar, Sasidharan Padmaja Divya, Sandeep Kumar Parvathareddy, Rong Bu, Tariq Masoodi, Yan Kong, Saravanan Thangavel, Nasser Al-Sanea, Luai H. Ashari, Alaa Abduljabbar, Samar Al-Homoud, Fouad Al-Dayel, and Khawla S. Al-Kuraya

1323 SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas Manuel Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, and Huai-Xiang Hao

ABOUT THE COVER

The growing cost of healthcare in oncology has incentivized researchers and physicians to repurpose clinically used drugs to reduce cost and time of development. The FDA-approved antiviral drug ribavirin epitomizes these efforts. Ribavirin has shown anticancer efficacy in preclinical and early clinical studies through various mechanisms of action including inhibition of protein translation (eIF4E), signaling pathways (ERK, MNK1), epigenetic modulators (EZH2), and cancer cell metabolism (IMPDH). Furthermore, several studies have suggested a beneficial use of ribavirin in combination with standard chemotherapies. These exciting properties position ribavirin to potentially “go viral” as a new adjuvant anticancer therapy. Image copyright owned by Johns Hopkins University, Ian Suk.



Molecular Cancer Therapeutics

18 (7)

Mol Cancer Ther 2019;18:1183-1334.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.